Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets.
about
Targeting FcRn for the modulation of antibody dynamicsUtilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum.Engineered monoclonal antibody with novel antigen-sweeping activity in vivo.First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled studyEvaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey PharmacokineticsChemically Modified Interleukin-6 Aptamer Inhibits Development of Collagen-Induced Arthritis in Cynomolgus Monkeys.Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosusFactors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis.Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methodsQualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments.Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases.Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn.A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition.Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.Quantitative measurements of GDF-8 using immunoaffinity LC-MS/MS.Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials.Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.A drug development perspective on targeting tumor-associated myeloid cells.Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model.The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria
P2860
Q28080589-0AC9B7B8-CB0F-45E0-8775-AA4C0F78A416Q30656754-CE24040E-3BA7-4606-BE44-6CD9F857A450Q33436512-10FE8DBC-C199-4CC4-A247-85502C610D15Q34223925-EDE513A5-52AE-47A8-BFCA-3074806CBAFBQ34718085-DDA6FD63-D2CB-4886-B51A-36EFA99CB7AEQ35195612-FC04EFCB-729A-49FB-A447-5F12F3FC3817Q36444225-F89653E8-FEA2-420B-8588-EA986626B0E3Q36579912-D7EAFB0C-1AFA-43ED-9B1C-9AAEBC0DFD89Q36806630-2B6C443C-7852-4142-928C-E0F295FBFC1CQ36951905-4CAA0DC4-1C4B-48A0-AFBD-FC10612F65F5Q37456300-8325F105-E80E-46B3-980B-74E1AF1BF32BQ38364466-70C80405-9A3C-4D90-8B1D-56DBB37142BEQ38856152-EF845877-61C5-458F-9C6C-C6D0FDE38A73Q38987211-1E234E91-DACA-4F37-8196-BE34F9B96582Q41775229-67C08C05-57A8-475A-B607-B39D12887653Q41787797-9EEDD11A-47F3-4EBC-9310-9AF710990E32Q41867620-A4969822-318E-4A98-AF34-F57C2C7DC787Q41953134-648E10C9-00D0-43B4-AC25-CCAAFF5D5C1EQ42135303-93E86B11-62BE-4838-9765-A10349D8E0EAQ42351659-937C8F1D-8E2F-4B81-9D0A-CF33C740E4ECQ42424619-00C8C74C-6563-46FC-A2CF-7ED6BFF8946BQ42584647-660269EF-27E8-411D-A253-C01622917293Q46600197-93EB6792-84BD-4084-ABEC-8324506635FAQ47630528-7263B86F-6AE5-492D-8AF4-4F3600C35613Q47663546-E5531A55-A747-4B42-AB52-7CA114426A4DQ48652546-5ACC9948-F7A0-4D43-848A-EE13C1531974Q53224491-A0C23E56-4548-43E5-9258-12910DC4623EQ53599930-D5B553D8-A9CA-48B7-847F-44C0E07BE4A3Q58566399-31E2FFC8-BEBC-41BD-A4F2-E633A270A775
P2860
Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targets.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Properties of a general PK/PD ...... to soluble endogenous targets.
@en
type
label
Properties of a general PK/PD ...... to soluble endogenous targets.
@en
prefLabel
Properties of a general PK/PD ...... to soluble endogenous targets.
@en
P2860
P356
P1476
Properties of a general PK/PD ...... to soluble endogenous targets.
@en
P2093
Jasmine P Davda
Ryan J Hansen
P2860
P304
P356
10.4161/MABS.2.5.12833
P577
2010-09-01T00:00:00Z